荷兰伊拉斯姆斯大学Joachim G. Aerts等研究人员合作发现，PD-1/PD-L1检查点抑制肿瘤引流淋巴结中的T细胞免疫。这一研究成果于2020年10月1日在线发表在国际学术期刊《癌细胞》上。

Title: The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

Author: Floris Dammeijer, Mandy van Gulijk, Evalyn E. Mulder, Melanie Lukkes, Larissa Klaase, Thierry van den Bosch, Menno van Nimwegen, Sai Ping Lau, Kitty Latupeirissa, Sjoerd Schetters, Yvette van Kooyk, Louis Boon, Antien Moyaart, Yvonne M. Mueller, Peter D. Katsikis, Alexander M. Eggermont, Heleen Vroman, Ralph Stadhouders, Rudi Hendriks, Jan von der Thüsen, Dirk J. Grünhagen, Cornelis Verhoef, Thorbald van Hall, Joachim G. Aerts

Issue&Volume: 2020-10-1

Abstract: PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-mediatedsuppression in the tumor microenvironment but PD-L1 is also expressed on non-tumormacrophages and conventional dendritic cells (cDCs). Here we show in mouse tumor modelsthat tumor-draining lymph nodes (TDLNs) are enriched for tumor-specific PD-1+ T cells which closely associate with PD-L1+ cDCs. TDLN-targeted PD-L1-blockade induces enhanced anti-tumor T cell immunity byseeding the tumor site with progenitor-exhausted T cells, resulting in improved tumorcontrol. Moreover, we show that abundant PD-1/PD-L1-interactions in TDLNs of nonmetastaticmelanoma patients, but not those in corresponding tumors, associate with early distantdisease recurrence. These findings point at a critical role for PD-L1 expression inTDLNs in governing systemic anti-tumor immunity, identifying high-risk patient groupsamendable to adjuvant PD-1/PD-L1-blockade therapy.

DOI: 10.1016/j.ccell.2020.09.001

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30432-3